| Aug 6 |
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 6 |
Repare Therapeutics GAAP EPS of -$0.82 beats by $0.03, revenue of $1.07M misses by $1.86M
|
| Aug 6 |
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
|
| Aug 1 |
We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
|
| Jul 23 |
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
|
| Jul 16 |
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
|
| Jun 26 |
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
|
| Jun 10 |
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
|
| Jun 6 |
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
|
| Jun 4 |
Repare gets FDA fast track status for ovarian cancer drug combo
|
